Clinical trial

Impact of Cystatin-C C-guided Vancomycin Dosing Recommendation on Target Trough Achievement and Clinical Outcomes in Critically Ill Adults

Name
14-002808
Description
Determine if a cystatin C-inclusive vancomycin dosing algorithm improved target trough achievement compared to creatinine clearance-guided vancomycin therapy in critically ill patients.
Trial arms
Trial start
2014-04-01
Estimated PCD
2015-06-01
Trial end
2016-03-01
Status
Completed
Phase
Early phase I
Treatment
Vancomycin
Intravenous
Arms:
Creatinine clearance guided vancomycin dosing, Cystatin C-guided vancomycin dosing algorithm
Other names:
Vancocin
Cystatin C dosing algorithm
Expressed in milliliters per minute
Arms:
Cystatin C-guided vancomycin dosing algorithm
Creatine clearance dosing algorithm
Vancomycin dosing algorithm based on creatinine clearance, expressed in milliliters per minute
Arms:
Creatinine clearance guided vancomycin dosing
Other names:
Cockcroft-Gault
Size
399
Primary endpoint
Vancomycin target trough achievement
Baseline
Eligibility criteria
Inclusion Criteria: * Hospitalized in one of three intensive care units at Mayo Clinic in Rochester, Minnesota * Suspected or documented gram-positive infection * Prescribed IV vancomycin at a consistent dose and scheduled with 8, 12, or 24 hour Vancomycin dosing interval Exclusion Criteria: * Vulnerable population * Received greater than 1 dose of Vancomycin in the 96 hours before ICU admission * Baseline glomerular filtration rate (GFR) of less than 20 milliliters/minute * Undergoing renal replacement therapy * Body mass index \> 40kg/m2 * Weight \< 40kg
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 399, 'type': 'ACTUAL'}}
Updated at
2023-10-10

1 organization

1 product

3 indications

Organization
Mayo Clinic
Product
Vancomycin
Indication
MRSA
Indication
Sepsis